Wells Fargo Maintains Equal-Weight on Conmed, Lowers Price Target to $107
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Durgesh Chopra has maintained an Equal-Weight rating on Conmed (NYSE:CNMD) and lowered the price target from $123 to $107.
October 26, 2023 | 12:56 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Conmed's price target has been lowered from $123 to $107 by Wells Fargo, while maintaining an Equal-Weight rating.
The lowering of the price target by a major financial institution like Wells Fargo could potentially lead to a decrease in Conmed's stock price in the short term. The Equal-Weight rating suggests that the stock is expected to perform in line with a specific benchmark over the next 12 months.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100